ES2104682T3 - Fluor-compuestos. - Google Patents

Fluor-compuestos.

Info

Publication number
ES2104682T3
ES2104682T3 ES91810940T ES91810940T ES2104682T3 ES 2104682 T3 ES2104682 T3 ES 2104682T3 ES 91810940 T ES91810940 T ES 91810940T ES 91810940 T ES91810940 T ES 91810940T ES 2104682 T3 ES2104682 T3 ES 2104682T3
Authority
ES
Spain
Prior art keywords
compounds
fluorine
prepared
formula
image
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91810940T
Other languages
English (en)
Inventor
Marc Dr Lang
Edmond Dr Differding
Jaroslav Dr Stanek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG, Novartis AG filed Critical Ciba Geigy AG
Application granted granted Critical
Publication of ES2104682T3 publication Critical patent/ES2104682T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32Antioestrogens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/26Radicals substituted by halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/041,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)

Abstract

COMPUESTO DE LA FORMULA I, EN LA QUE Z, R, R SUB 1, R SUB 2 Y X TIENEN, EN LA DESCRIPCION, UN SIGNIFICADO DETERMINADO, PRESENTAN CUALIDADES FARMACEUTICAS VALIOSAS Y SON ESPECIALMENTE ACTIVOS CONTRA TUMORES. SE PRODUCEN DE UNA FORMA CONOCIDA EN SI.
ES91810940T 1990-12-12 1991-12-03 Fluor-compuestos. Expired - Lifetime ES2104682T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH392390 1990-12-12

Publications (1)

Publication Number Publication Date
ES2104682T3 true ES2104682T3 (es) 1997-10-16

Family

ID=4266402

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91810940T Expired - Lifetime ES2104682T3 (es) 1990-12-12 1991-12-03 Fluor-compuestos.

Country Status (18)

Country Link
US (4) US5227393A (es)
EP (1) EP0490816B1 (es)
JP (1) JP3133432B2 (es)
KR (1) KR100214353B1 (es)
AT (1) ATE155130T1 (es)
AU (1) AU649499B2 (es)
CA (1) CA2057338C (es)
DE (1) DE59108770D1 (es)
DK (1) DK0490816T3 (es)
ES (1) ES2104682T3 (es)
GR (1) GR3024191T3 (es)
IE (1) IE914312A1 (es)
IL (1) IL100266A (es)
NZ (1) NZ240925A (es)
PH (1) PH30675A (es)
PT (1) PT99738B (es)
TW (1) TW210334B (es)
ZA (1) ZA919752B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW224461B (es) * 1990-09-18 1994-06-01 Ciba Geigy Ag
TW210334B (es) * 1990-12-12 1993-08-01 Ciba Geigy Ag
WO1994008973A1 (en) * 1992-10-21 1994-04-28 Sankyo Company, Limited Azole compound
US5426196A (en) * 1993-12-22 1995-06-20 Glaxo Inc. Synthesis of diaryl methanes
IT1286866B1 (it) * 1996-10-28 1998-07-17 Menarini Farma Ind Composti furano-eterociclici,loro preparazione ed uso come inibitori di aromatasi
FI20010905A0 (fi) * 2001-05-02 2001-05-02 Vetcare Oy Uusi eläinlääke
GB0914767D0 (en) * 2009-08-24 2009-09-30 Sterix Ltd Compound
CN102884072A (zh) 2010-04-08 2013-01-16 爱默蕾大学 被取代的雄甾-4-烯二酮
AU2012304694B2 (en) * 2011-09-08 2016-04-07 Mereo Biopharma 2 Limited Pharmaceutical compositions comprising an aromatase inhibitor
CN107074841B (zh) 2014-08-11 2021-03-26 安吉恩生物医药公司 细胞色素p450抑制剂及其用途
WO2016109492A1 (en) 2014-12-31 2016-07-07 Angion Biomedica Corp Methods and agents for treating disease
GB201614179D0 (en) 2016-08-19 2016-10-05 Mereo Biopharma 2 Ltd Dosage regimen for the treatment of endometriosis

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2407305C2 (de) * 1974-02-15 1984-06-28 Bayer Ag, 5090 Leverkusen Triphenyl-1,2,3-triazol-1-yl-methane, Verfahren zu ihrer Herstellung und ihre Verwendung als Fungizide
GB1511195A (en) * 1976-10-18 1978-05-17 Ici America Inc Triazole derivatives
GB1555417A (en) * 1977-04-19 1979-11-07 Ici America Inc Triazole compositions
NZ206968A (en) * 1983-02-02 1986-06-11 Lilly Co Eli Pyrimidine derivatives pharmaceutical formulations
US4762836A (en) * 1983-02-02 1988-08-09 Eli Lilly And Company Aromatase inhibitors
GB8305377D0 (en) * 1983-02-25 1983-03-30 Pfizer Ltd Antifungal agents
ATE46150T1 (de) * 1984-05-23 1989-09-15 Ciba Geigy Ag Mikrobizide 1-fluor-1-azolyl-2,2diarylethanderivate.
US4609666A (en) * 1984-06-18 1986-09-02 Eli Lilly And Company Aromatase inhibiting derivatives of α,α-bis(4-halophenyl)methyltetrazoles and triazoles
US4764376A (en) * 1984-06-18 1988-08-16 Eli Lilly And Company Method of inhibiting aromatase
US4845227A (en) * 1984-06-18 1989-07-04 Eli Lilly And Company Aromatase inhibitors from azoles
US4757076A (en) * 1984-06-18 1988-07-12 Eli Lilly And Company Method of inhibiting aromatase
US4937250A (en) * 1988-03-07 1990-06-26 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
US4749713A (en) * 1986-03-07 1988-06-07 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
US5071861A (en) * 1986-03-07 1991-12-10 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
US4978672A (en) * 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
US5352795A (en) * 1986-03-07 1994-10-04 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
US5112845A (en) * 1986-03-07 1992-05-12 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
DE3627310A1 (de) * 1986-08-12 1988-02-18 Biotechnolog Forschung Gmbh Pyocyanin-derivate und herstellungsverfahren
JPS63165376A (ja) * 1986-12-27 1988-07-08 Nippon Soda Co Ltd オキサ(チア)ジアゾ−ル誘導体その製造方法及び殺ダニ剤
NZ224714A (en) * 1987-06-01 1990-03-27 Janssen Pharmaceutica Nv Substituted benzotriazole derivatives and pharmaceutical compositions
GB8716651D0 (en) * 1987-07-15 1987-08-19 Ici Plc 2-propanol derivatives
GB8716650D0 (en) * 1987-07-15 1987-08-19 Ici Plc Use of olefinic compounds
DE3811574A1 (de) * 1988-03-31 1989-10-19 Schering Ag N-substituierte imidazole, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
DE3819903A1 (de) * 1988-06-11 1989-12-21 Basf Ag 1-halogen-1-azolyl-ethan-derivate und diese enthaltende fungizide
GB8818561D0 (en) * 1988-08-04 1988-09-07 Ici Plc Diphenylethane derivatives
ES2084687T3 (es) * 1989-07-14 1996-05-16 Ciba Geigy Ag Benzonitrilos substituidos.
AU7124691A (en) * 1990-02-27 1991-08-29 Ciba-Geigy Ag Benzofurans
TW224461B (es) * 1990-09-18 1994-06-01 Ciba Geigy Ag
TW210334B (es) * 1990-12-12 1993-08-01 Ciba Geigy Ag

Also Published As

Publication number Publication date
ATE155130T1 (de) 1997-07-15
EP0490816B1 (de) 1997-07-09
IE914312A1 (en) 1992-06-17
JPH04300866A (ja) 1992-10-23
GR3024191T3 (en) 1997-10-31
NZ240925A (en) 1995-02-24
PH30675A (en) 1997-09-16
IL100266A (en) 1996-05-14
IL100266A0 (en) 1992-09-06
AU8889991A (en) 1992-07-09
CA2057338C (en) 2002-09-17
KR100214353B1 (ko) 1999-08-02
PT99738B (pt) 1999-05-31
DE59108770D1 (de) 1997-08-14
US5637605A (en) 1997-06-10
US5376669A (en) 1994-12-27
ZA919752B (en) 1992-08-26
AU649499B2 (en) 1994-05-26
JP3133432B2 (ja) 2001-02-05
TW210334B (es) 1993-08-01
DK0490816T3 (da) 1997-09-22
EP0490816A2 (de) 1992-06-17
EP0490816A3 (en) 1992-12-02
CA2057338A1 (en) 1992-06-13
PT99738A (pt) 1992-12-31
US5227393A (en) 1993-07-13
KR920012049A (ko) 1992-07-25
US5457209A (en) 1995-10-10

Similar Documents

Publication Publication Date Title
ES2046527T3 (es) Arilhidrazona.
ES2104682T3 (es) Fluor-compuestos.
ES2084687T3 (es) Benzonitrilos substituidos.
KR960703863A (ko) 암 치료용 신규 비스-나프탈이미드(New Bis-naphthalimides for the Treatment of Cancer)
ES2098338T3 (es) Heteroarilmetilbencenos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 490816

Country of ref document: ES